Drugs / Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00217373 Background | Jun 2005 → Jan 2013 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00217373 ↗ |
| Action | Deplete | “Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells that make carcinoembryonic antigen (CEA).” NCT00217373 ↗ |
| Modality | Vaccine | “Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells that make carcinoembryonic antigen (CEA).” NCT00217373 ↗ |
| Route | Subcutaneous | “Given SC” NCT00217373 ↗ |